CILO CYBIN: Groundbreaking Pharmaceutical Magic That Changes Lives

“Cilo Cybin was established in 2018 with the vision to transform lives through accessible, effective medical cannabis products,” unpacks CEO Gabriel Theron, with the company’s commitment to scientific research, innovation and high-quality standards ensuring that these products make a genuine impact on users while establishing Cilo Cybin as a genuine industry great.

“Cilo Cybin is dedicated to bringing medical cannabis products to markets worldwide, including Australia, Japan, Thailand, and other countries recognising South African Health Products Regulatory Authority (SAHPRA) Good Manufacturing Practices (GMP) accreditation,” Theron details, of goods known for offering rapid absorption, precise dosing and targeted relief, to establish them as ideal for various medical applications.

“By adhering to the highest standards of GMP cannabis manufacturing, Cilo Cybin ensures that our medical cannabis products are safe, effective and reliable.”

TARGETING EXPANSION

The company’s core focus is on supplying GMP medical cannabis products, Theron details, to meet the highest standards of quality, effectiveness, care and safety. Two key arms comprise the overall company: state of the art, indoor medical-grade cannabis cultivation in accordance with Good Agricultural and Collection Practices (GACP) and extraction of the cannabis flower, trim and kief with a cold ethanol process. “The former is on a small scale, and very boutique, with production of around 50-60 kilos per month possible of triple A-grade dried cannabis flower,” Theron says.

“Cilo Cybin’s cultivation facility provides us with the purest and most consistent flower, ensuring a medical-grade product that is used both in-house to create our world-class cannabis-derived supplements and medications, as well as internationally. On the extraction side we use both the trim and buy in products to extract, and current capacity is around 100 kilos of biomass per week.

“We are busy with expansion of this ability, and by the end of this calendar year we are aiming to be capable of processing 10 times this amount – a tonne a week.” From this point follows distillation, Theron further expounds, where the crude oil extracted is purified, which is due to be subject to a similar increase from 10 to 100 litres per week. “This will place us as one of the largest on the continent,” Theron reveals.

Various product lines then result from the raw product, including bottling, vaping and an imminent edible range with an accompanying new laboratory, set to multiple this capacity tenfold, too. “Cilo Cybin is also one of the few licensed facilities that is allowed to package finished cannabis products under GMP in South Africa for the local and export markets,” Theron adds.

“We are, today, the only fully vertically integrated cannabis company in the country, meaning that we alone can both cultivate and extract to make final products under one roof. Quality is a further key differentiator for us, due to the regulatory environment associated with South Africa compared to the likes of Colombia, for example, allowing us to compete in the global market.”

The vast majority of Cilo Cybin’s wares are crafted for export, Theron explains, due to the difficulty of selling within South Africa. “Australia is currently one of our largest markets,” he says, “while Europe is central on our radar in terms of our next move.” There has been a definite maturity in the market in the last 12 months, however, Theron perceives, and an uptick in terms of these products landing up in patients’ hands. “We have certainly felt it become easier to operate in, and sell products into, this space – now price and quality become paramount, which suits us perfectly.”

HISTORIC LISTING

Having been the first South African company to win the right to grow, process and package cannabis goods, Cilo Cybin this year racked up another first, this time doing like no-one medical cannabis company ever before it and listing on the Johannesburg Stock Exchange’s Alternative Exchange. The move is part of a concerted bid to capitalise on growth in the legal marijuana industry, which is projected, Theron shares, to grow to more than $40 billion by 2032 – from $12.6 billion in 2023.

“As the markets mature, we want to be at the forefront of taking advantage of them,” Theron details of the rationale behind the listing, with funds raised set to help the company, “tap into the growing global investor appetite for alternative medicines,” he adds.

“The entity on the Alt-X is Cilo Cybin Holdings,” Theron further unpacks. “The intention is that it will then acquire a 100% stake of Cilo Cybin Pharmaceuticals, in the form of a share swap, resulting in an entity with no debt, funds in the bank and the ability to scale very quickly.” Following the combination of the entities, Theron explains, the next step is to start clinical trials for product lines in the cannabis stage, including for drug-resistant epilepsy, before pursuing a Nasdaq for Cilo Cybin listing within the next two to three years.

Theron’s vision is broad, with a keen eye on involvement in psychedelics, but with cannabis always as the starting point, and current priority. “We have some work to do before we can confidently apply our energies elsewhere,” Theron smiles. “Even our name points to a move to psychedelics as having been in the offing right from the beginning,” he qualifies, taken as it was directly from that of the key ingredient in magic mushrooms. “We adopted it intentionally, in full knowledge that it was cheeky and risqué,” he closes. “We want to play in the pharmaceutical world, but with alternative, edgy things as well, and we can see that the world is moving that way.

“We set out to be a new-age, new-thinking pharmaceutical company,” Theron stipulates, “and this has always been the pathway that we have seen ourselves following. We are taking a name, and a concept, and declaring loudly and proudly to people that something which was maybe taboo 10 years ago has now been turned on its head.

“This is how we see ourselves: as we apply our capabilities and expertise to ensure the highest standards of quality and compliance, we want to be the ingredient in the pharmaceutical world that makes the magic.”